Clinical trialNCT03383094Active, not recruitingPhase 2Interventional

Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer

SponsorLoren Mell, MDEnrollment126CancerCancer of Head and NeckCancer, AdvancedCancer, MetastaticHead and Neck Squamous Cell CarcinomaOral Cancer+9 more conditions

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to compare any good or bad effects of using pembrolizumab (an experimental drug) and radiation therapy (RT), compared to using cisplatin chemotherapy and radiation therapy (RT) in the treatment of patients with head and neck squamous cell carcinoma (HNSCC).

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Loren Mell, MD
University of California, San Diego
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

University of Arizona Cancer Center
Tucson, Arizona, United States
Uc San Diego Moores Cancer Center
La Jolla, California, United States
H. Lee Moffitt Cancer Center & Research Facility
Tampa, Florida, United States
Washington University School of Medicine, Siteman Cancer Center
St Louis, Missouri, United States
University of Cincinnati Medical Center
Cincinnati, Ohio, United States
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Cisplatin →Pembrolizumab →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 15 Mar 2018
Primary completion: 31 Dec 2026
Completion: 31 Dec 2027
Last update posted: 7 Oct 2025
Registered enrollment: 126
Registry id: NCT03383094

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.